uri,title,text,type,authors,tags,organisation,date
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/001_Hogg.pdf,Abstract 1,A new level of control of thrombosis,Plenary 3,Phil Hogg,Barry Firkin Oration,ACRF Centenary Cancer Research Centre,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/002_Wood.pdf,Abstract 2,Karl Landsteiner was on to something,Plenary 3,Erica Wood,Ruth Sanger Oration,Monash University,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/003_Iland.pdf,Abstract 3,"Curing acute promyelocytic leukaemia - blunderbuss, vitamins, and a poison||chaser",Plenary 3,Harry Iland,Carl de Gruchy Oration,The University of Sydney,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/004_Crighton.pdf,Abstract 4,Use of ferric carboxymaltose in children,Meeting Room 212 & 213,Gemma Crighton,ANZSBT Presidential Symposium,Royal Children's Hospital,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/005_Flores.pdf,Abstract 5,Improving blood management in obstetrics: a practice improvement partnership,Meeting Room 212 & 213,Cindy Flores,ANZSBT Presidential Symposium,Australian Red Cross Blood Service,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/006_Dean.pdf,Abstract 6,Development of laboratory assays for multiple parallel assessments of recipient||immune responses for use in clinical studies of transfusion outcomes,Meeting Room 212 & 213,Melinda Dean,ANZSBT Presidential Symposium,Australian Red Cross Blood Service,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/007_McQuilten.pdf,Abstract 7,Epidemiology and outcomes of major obstetric haemorrhage requiring massive||transfusion in Australia and New Zealand: Results from the Australasian||Maternity Outcomes Surveillance System (AMOSS),Meeting Room 212 & 213,Zoe McQuilten,ANZSBT Presidential Symposium,Monash University,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/008_Hyland.pdf,Abstract 8,Non Invasive Prenatal Testing (NIPT) for fetal RHD in twin pregnancies,Meeting Room 212 & 213,Catherine Hyland,ANZSBT Presidential Symposium,Australian Red Cross Blood Service,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/009_Mithraprabhu.pdf,Abstract 9,Circulating free tumour DNA analysis demonstrates spatial mutational||heterogeneity that coincides with disease relapse in multiple myeloma patients,Plenary 3,Durga Mithraprabhu,Combined HSANZ / ASTH Presidential Symposium,Alfred Health - Monash University,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/010_Dyer.pdf,Abstract 10,The occupational and financial impact of Blood and Marrow Transplantation (BMT)||on long-term survivors of BMT in NSW,Plenary 3,Gemma Dyer,Combined HSANZ / ASTH Presidential Symposium,University of Sydney,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/011_Kalff.pdf,Abstract 11,ROAR: A Phase Ib trial of oral azacitidine in combination with lenalidomide and||dexamethasone (Rd) for patients with relapsed and/or refractory (R/R) multiple||myeloma who have failed a prior lenalidomide-containing regimen,Plenary 3,Anna Kalff,Combined HSANZ / ASTH Presidential Symposium,"Myeloma Research Group, The Alfred Hospital, Monash University",14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/012_Asari.pdf,Abstract 12,Point mutations in TKI-resistant Ph-like acute lymphoblastic leukaemia via In||vitro modelling: - implications for targeted therapeutic approaches,Plenary 3,Kartini Asari,Combined HSANZ / ASTH Presidential Symposium,South Australian Health and Medical Research Institute (SAHMRI),14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/013_Rabbolini.pdf,Abstract 13,Platelet development and bleeding phenotype is altered with mutation in||different zinc finger domains of the GFI1B transcription factor,Meeting Room 219,David Rabbolini,Combined HSANZ / ASTH Presidential Symposium,Royal North Shore Hospital,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/014_Tay.pdf,Abstract 14,Validation of plasma miR-494-3p and miR-365a-3p expression levels as indicators||of thrombotic risk,Meeting Room 219,Jasmine Tay,Combined HSANZ / ASTH Presidential Symposium,WACTH,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/015_Spencer.pdf,Abstract 15,Biology of multiple myeloma: Genetics and epigenetics,Plenary 3,Andrew Spencer,HSANZ Symposium: Myeloma - the science and therapeutic update,Malignant Haematology and Stem Cell Transplantation Service,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/016_Facon.pdf,Abstract 16,Optimal treatment in de novo and first relapse myeloma,Plenary 3,Thierry Facon,HSANZ Symposium: Myeloma - the science and therapeutic update,CHRU de Lille - Hôpital Claude Huriez,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/017_Kurtin.pdf,Abstract 17,LIVING with Cancer:  From the lens of a caregiver,Plenary 3,Sandra Kurtin,HSANZ & Nurses Symposium Survivorship,The University of Arizona Cancer Center,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/018_Avery.pdf,Abstract 18,Optimising survivorship - The physicians perspective,Plenary 3,Sharon Avery,HSANZ & Nurses Symposium Survivorship,The Alfred,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/019_Green.pdf,Abstract 19,The myeloproliferative neoplasms - JAK/STAT signalling and stem cell subversion||,Plenary 3,Tony Green,HSANZ/EHA Symposium: Myeloid disorders,University of Cambridge,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/020_Dick.pdf,Abstract 20,Clinical relevance of leukemia stem cells in AML||,Plenary 3,John Dick,HSANZ/EHA Symposium: Myeloid disorders,University of Toronto,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/021_McLintock.pdf,Abstract 21,Thrombocytopenia in pregnancy,Plenary 3,Claire McLintock,"COMBINED SYMPOSIUM (HSANZ, ANZSBT, ASTH & Nurses): Haematological diseases in pregnancy",National Women's Health,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/022_Hamilton.pdf,Abstract 22,Blood Cancer & Pregnancy - Practical management,Plenary 3,Anne Hamilton,"COMBINED SYMPOSIUM (HSANZ, ANZSBT, ASTH & Nurses): Haematological diseases in pregnancy",Peter MacCallum Cancer Centre,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/023_Savoia.pdf,Abstract 23,Alloummunisation - what's new?,Plenary 3,Helen Savoia,"COMBINED SYMPOSIUM (HSANZ, ANZSBT, ASTH & Nurses): Haematological diseases in pregnancy",The Royal Children's Hospital,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/024_Yeh.pdf,Abstract 24,Circulating tumour DNA reflects overall disease burden and clonal evolution in||chronic lymphocytic leukemia.,Plenary 3,Paul Yeh,HSANZ Early Career Symposium,Peter MacCallum Cancer Centre,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/025_Henden.pdf,Abstract 25,Interferon Lambda  is a Critical Cytoprotectant in Bone Marrow Transplantation||,Plenary 3,Andrea Henden,HSANZ Early Career Symposium,QIMR Berghofer Medical Research Institute,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/026_Anderson.pdf,Abstract 26,BCL2 selective inhibition with venetoclax induces apoptosis in high risk||del(17p) and TP53-defective CLL in vitro and in patients leading to durable||responses,Plenary 3,Mary Ann Anderson,HSANZ Early Career Symposium,"Cancer and Haematology Division, Walter and Eliza Hall Institute",14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/027_Hsu.pdf,Abstract 27,Therapeutic blood dendritic cell vaccination for acute myeloid leukaemia,Plenary 3,Jennifer Hsu,HSANZ Early Career Symposium,ANZAC Research Institute,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/028_Yannakou.pdf,Abstract 28,Germline variant detection by next generation sequencing in routine tumour||sample analysis - mountain or molehill?,Plenary 3,Costas Yannakou,HSANZ Early Career Symposium,Peter MacCallum Cancer Centre,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/029_Low.pdf,Abstract 29,Identifying downstream targets of IRF4 for therapeutic targeting in myeloma.,Plenary 3,Michael Low,HSANZ Early Career Symposium,Walter and Eliza Hall Institute of Medical Research,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/030_Friedberg.pdf,Abstract 30,Novel agents - who needs them?,Plenary 3,Jonathan W. Friedberg,HSANZ Symposium: Indolent lymphoma,James P. Wilmot Cancer Institute,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/031_Treon.pdf,Abstract 31,Genomic based treatment advances in Waldenstrom's Macroglobulinemia,Plenary 3,Steven Treon,HSANZ Symposium: Indolent lymphoma,Harvard Medical School,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/032_Renwick.pdf,Abstract 32,A Frailty Scale Predicts Outcomes in Transplant-Ineligible Patients With||Newly-Diagnosed Multiple Myeloma (NDMM) Treated in the FIRST Trial With||Continuous Lenalidomide Plus Low-Dose Dexamethasone (Rd),Plenary 3,William Renwick,HSANZ Free Communications 1: Myeloma Clinical I,Western Health,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/033_Scott.pdf,Abstract 33,Real-world’ Australian experience of pomalidomide for relapsed/refractory||myeloma,Plenary 3,Ashleigh Scott,HSANZ Free Communications 1: Myeloma Clinical I,Princess Alexandra Hospital,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/034_Simpson.pdf,Abstract 34,Myeloma outcomes in New Zealand: Increasing regional variation,Plenary 3,David Simpson,HSANZ Free Communications 1: Myeloma Clinical I,North Shore Hospital,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/035_Wong Doo.pdf,Abstract 35,Early autologous stem cell transplant associated with improved overall survival||in multiple myeloma: findings from a population based study,Plenary 3,Nicole Wong Doo,HSANZ Free Communications 1: Myeloma Clinical I,Concord Hospital,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/036_Taylor.pdf,Abstract 36,Transplantation in FLT-3-ITD+ AML with normal karyotype is associated with||improved overall survival,Meeting Room 217,Emma Taylor,HSANZ Free Communications 2: Bone Marrow Transplantation,Royal Brisbane & Women's Hospital,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/037_Wong.pdf,Abstract 37,The Prognostic Impact Of Early Donor Chimerism After Allogeneic Stem Cell||Transplantation Is Dependent On Disease Risk Index.,Meeting Room 217,Eric Wong,HSANZ Free Communications 2: Bone Marrow Transplantation,Royal Melbourne Hospital,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/038_Wright.pdf,Abstract 38,"Biopsychosocial Outcomes of Victorian Allogeneic Stem Cell Transplant (alloSCT)||Late Effects (LE) Program: Metabolic Syndrome (MetS), Quality of Life  (QOL) &||Returning to Work",Meeting Room 217,Tricia Wright,HSANZ Free Communications 2: Bone Marrow Transplantation,Alfred Health,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/039_Birchley.pdf,Abstract 39,"Early acute kidney injury post allogeneic stem cell transplant is associated||with increased risk of GVHD, higher mortality and reduced survival",Meeting Room 217,Andrew Birchley,HSANZ Free Communications 2: Bone Marrow Transplantation,Royal Brisbane & Women's Hospital,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/040_Bennett.pdf,Abstract 40,Inhibition of glucosylceramide synthase induces apoptotic cell death in multiple||myeloma cells,Meeting Room 218,Melissa Bennett,HSANZ Free Communications 3: Myeloma Biology,Centre for Cancer Biology,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/041_Nair.pdf,Abstract 41,Application of EuroFlow for minimal residual disease detection of multiple||myeloma following tandem autologous-NMA allogeneic stem cell transplantation,Meeting Room 218,Anish Nair,HSANZ Free Communications 3: Myeloma Biology,"Alfred Hospital, Melbourne",14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/042_Reale.pdf,Abstract 42,TOP2A a New Predictive Marker of Response to Carfilzomib in Multiple Myeloma,Meeting Room 218,Antonia Reale,HSANZ Free Communications 3: Myeloma Biology,ACBD Monash University - The Alfred,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/043_Savvidou.pdf,Abstract 43,Overcoming innate resistance to a new beta-catenin inhibitor by manipulating the||autophagic pathway in Multiple Myeloma,Meeting Room 218,Ioanna Savvidou,HSANZ Free Communications 3: Myeloma Biology,"Monash University, Alfred Hospital, Myeloma Research Group",14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/044_Forsyth.pdf,Abstract 44,The Delayed Diagnosis of Philadelphia Negative Myeloproliferative Neoplasms||(MPN) is Common and Results in a High Incidence of Potentially Preventable||Thrombotic Complications.,Meeting Room 211,Cecily Forsyth,HSANZ Free Communications 4: Myeloproliferative Disorders,Gosford Haematology,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/045_Hughes.pdf,Abstract 45,Immune Responses in Chronic Myeloid Leukaemia Patients Following Cessation of||Tyrosine Kinase Inhibitor||,Meeting Room 211,Amy Hughes,HSANZ Free Communications 4: Myeloproliferative Disorders,South Australia Health and Medical Research Institute,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/046_Pagani.pdf,Abstract 46,Mitochondrial DNA mutations at diagnosis are linked to response in TKI treated||chronic myeloid leukaemia patients,Meeting Room 211,Ilaria Stefania Pagani,HSANZ Free Communications 4: Myeloproliferative Disorders,South Australian Health and Medical Research Institute (SAHMRI),14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/047_Ryland.pdf,Abstract 47,Targeted amplicon sequencing combined with selected extended sequencing||efficiently establishes diagnoses in conventional and triple-negative BCR-ABL||negative myeloproliferative neoplasms in the molecular diagnostic laboratory,Meeting Room 211,Georgie Ryland,HSANZ Free Communications 4: Myeloproliferative Disorders,Peter MacCallum Cancer Centre,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/048_Treon.pdf,Abstract 48,Biology and Therapy of Waldenstrom’s Macroglobulinemia,Meeting Room 217,Steven Treon,HSANZ Masterclass: Waldenstroms (Steven Treon),Harvard Medical School,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/049_Green.pdf,Abstract 49,Clinician scientists – bridging the MPN divide,Meeting Room 218,Tony Green,HSANZ Masterclass: MPN (Anthony Green),University of Cambridge,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/050_Shortt.pdf,Abstract 50,Single hit lymphoma,Plenary 3,Jake Shortt,HSANZ Symposium: Aggressive lymphoma,Monash Health,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/051_Trotman.pdf,Abstract 51,Ann Arbor Staging vs. Total Metabolic Tumour Volume. Time for a change?,Plenary 3,Judith Trotman,HSANZ Symposium: Aggressive lymphoma,Concord Hospital,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/052_Hertzberg.pdf,Abstract 52,Hodgkin lymphoma gone bad,Plenary 3,Mark Hertzberg,HSANZ Symposium: Aggressive lymphoma,Prince of Wales Hospital,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/053_Juneja.pdf,Abstract 53,The 2016 revision of the WHO classification of myeloid neoplasms & acute||leukaemia,Meeting Room 216,Surender Juneja,Lab Haematology Symposium 1: MDS and AML,Royal Melbourne Hospital,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/054_Blombery.pdf,Abstract 54,Update on molecular diagnostics of AML & MDS,Meeting Room 216,Piers Blombery,Lab Haematology Symposium 1: MDS and AML,Peter MacCallum Cancer Centre,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/055_Viprakasit.pdf,Abstract 55,Novel therapies in thalassaemia,Plenary 3,Vip Viprakasit,HSANZ & ANZSBT: Haemoglobinopathies,"Siriraj Hospital, Mahidol University",15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/056_Ware.pdf,Abstract 56,Global strategies for sickle cell disease,Plenary 3,Russell Ware,HSANZ & ANZSBT: Haemoglobinopathies,Cincinnati Children's Hospital,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/057_Jane.pdf,Abstract 57,Towards novel therapies for the hemoglobinopathies,Plenary 3,Stephen Jane,HSANZ & ANZSBT: Haemoglobinopathies,Monash University,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/058_Young.pdf,Abstract 58,Aplastic anemia: Treating the hematopoietic stem cell,Plenary 3,Neal Young,HSANZ Symposium: Aplastic Anaemia,"National Heart, Lung & Blood Institute",15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/059_Firkin.pdf,Abstract 59,Objectives and progress of the Australian Aplastic Anaemia Registry,Plenary 3,Frank Firkin,HSANZ Symposium: Aplastic Anaemia,St Vincent's Hospital,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/060_Lade.pdf,Abstract 60,Update on 2016 WHO classification of lymphoid neoplasms,Meeting Room 216,Stephen Lade,Lab Haematology Symposium 2,Peter MacCallum Cancer Centre,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/061_Sartor.pdf,Abstract 61,A review of the RCPA EQA program for paroxysmal nocturnal haemoglobinuria,Meeting Room 216,Mary Sartor,Lab Haematology Symposium 2,Westmead Hospital,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/062_Huang.pdf,Abstract 62,The science behind BcL2 inhibition,Plenary 3,David Huang,HSANZ Symposium: Bcl2 inhibition - The science and clinical impact,Walter & Eliza Hall Institute of Medical Research,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/063_Anderson.pdf,Abstract 63,Bcl2 inhibition in lymphoproliferative disease,Plenary 3,Mary Ann Anderson,HSANZ Symposium: Bcl2 inhibition - The science and clinical impact,"Cancer and Haematology Division, Walter and Eliza Hall Institute",15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/064_Wei.pdf,Abstract 64,Therapeutic progress in targeting apoptosis pathways in AML,Plenary 3,Andrew Wei,HSANZ Symposium: Bcl2 inhibition - The science and clinical impact,The Alfred Hospital and Monash University,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/065_Friedberg.pdf,Abstract 65,Precision approach to Follicular Lymphoma,Meeting Room 216,Jonathan W. Friedberg,HSANZ Masterclass: Lymphoma (Jonathan Friedberg),James P. Wilmot Cancer Institute,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/066_Facon.pdf,Abstract 66,Myeloma: Front line therapy in transplant ineligible patients,Meeting Room 217,Thierry Facon,HSANZ Masterclass: Myeloma (Theirry Facon),CHRU de Lille - Hôpital Claude Huriez,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/067_Young.pdf,Abstract 67,Constitutional bone marrow failure syndromes manifesting in adults,Meeting Room 218,Neal Young,HSANZ Masterclass: Bone marrow failure (Neal Young),"National Heart, Lung & Blood Institute",15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/068_Wong.pdf,Abstract 68,99m Technetium-hydroxy-diphosphate Tracer (99mTcHDP) Bone Scintigraphy: A||Non-invasive Diagnostic Tool for Cardiac Amyloidosis||,Plenary 3,Caroline Wong,HSANZ Free Communications 5: Myeloma Clinical II,Eastern Health,16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/069_Bergin.pdf,Abstract 69,Rates of upfront autologous stem cell transplantation (ASCT) in newly diagnosed||multiple myeloma (NDMM):  a report from the MRDR on behalf of the MRDR steering||committee,Plenary 3,Krystal Bergin,HSANZ Free Communications 5: Myeloma Clinical II,The Alfred,16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/070_Gibbs.pdf,Abstract 70,"Monoclonal antibodies in systemic AL amyloidosis - when it rains, in pours",Plenary 3,Simon Gibbs,HSANZ Free Communications 5: Myeloma Clinical II,"The Victorian and Tasmanian Amyloidosis Service, Monash University Eastern Healt",16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/071_Kalff.pdf,Abstract 71,A 2-stage phase II study of panobinostat consolidation in Multiple Myeloma (MM)||patients with < CR Following High-Dose Chemotherapy (HDT) conditioned Autologous||Stem Cell Transplantation (ASCT) as part of first line therapy,Plenary 3,Anna Kalff,HSANZ Free Communications 5: Myeloma Clinical II,"Myeloma Research Group, The Alfred Hospital, Monash University",16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/072_Liedtke.pdf,Abstract 72,NEOD001 demonstrates organ biomarker responses in patients with light chain||amyloidosis and persistent organ dysfunction: results from the expansion phase||of a phase 1/2 study,Plenary 3,Michaela Liedtke,HSANZ Free Communications 5: Myeloma Clinical II,Stanford University Medical School,16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/073_Moore.pdf,Abstract 73,Renal impairment in myeloma: a comparison of characteristics and outcomes in||patients with and without renal impairment in the Australia and New Zealand||myeloma and related diseases registry,Plenary 3,Elizabeth Moore,HSANZ Free Communications 5: Myeloma Clinical II,Monash University,16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/074_Blombery.pdf,Abstract 74,Genomic characterisation of breast implant-associated anaplastic large cell||lymphoma reveals a high incidence of activating JAK1/STAT3 mutations and||identifies predisposing germline variants,Meeting Room 216,Piers Blombery,HSANZ Free Communications 6: Lymphoma,Peter MacCallum Cancer Centre,16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/075_Falconer.pdf,Abstract 75,The frequency of incidental malignancies detected by PET/CT scans in patients||with lymphoma and the associated clinical implications,Meeting Room 216,Janlyn Falconer,HSANZ Free Communications 6: Lymphoma,Westmead Hospital,16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/076_Ratnasingam.pdf,Abstract 76,Improved survival of older patients with Mantle Cell Lymphoma (MCL) with||cytarabine-based immunochemotherapy.,Meeting Room 216,Sumita Ratnasingam,HSANZ Free Communications 6: Lymphoma,Monash Health,16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/077_Roberts.pdf,Abstract 77,Frequent achievement of complete remissions in patients with relapsed /||refractory mantle cell lymphoma treated with the combination of Ibrutinib and||Venetoclax (ABT-199): results from the ongoing Australian Phase 2 AIM study,Meeting Room 216,Constantine Tam,HSANZ Free Communications 6: Lymphoma,Peter MacCallum Cancer Centre,16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/078_Tang.pdf,Abstract 78,Primary central nervous system lymphoma: a tertiary institution experience over||the last decade,Meeting Room 216,Catherine Tang,HSANZ Free Communications 6: Lymphoma,Royal North Shore Hospital,16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/079_van der Weyden.pdf,Abstract 79,A Retrospective Review of Treatment Outcomes in Patients Treated for Peripheral||T Cell Lymphoma (PTCL) at the Peter MacCallum Cancer Centre (PMCC) between 1999||and 2015,Meeting Room 216,Carrie van der Weyden,HSANZ Free Communications 6: Lymphoma,Peter MacCallum Cancer Centre,16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/080_Chunilal.pdf,Abstract 80,Safety of RAPid INJECTion of Undiluted Ferric Carboxymaltose to Patients with||Iron Deficiency Anaemia (RAPINJECT).,Meeting Room 217,Sanjeev Chunilal,HSANZ Free Communications 7: Non-Malignant,Monash Medical Centre,16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/081_Ho.pdf,Abstract 81,"Prevalence of cardiac and hepatic siderosis in Australian patients with||transfusion-dependent anaemias or non-transfusion-dependent thalassaemia, as||assessed by MRI (the TIMES Study)",Meeting Room 217,P. Joy Ho,HSANZ Free Communications 7: Non-Malignant,Royal Prince Alfred Hospital,16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/082_Hsu.pdf,Abstract 82,"An Observational, Non-Interventional, Multicentre,  Registry Of Patients With||Atypical Haemolytic Uraemic Syndrome (aHUS): A Review Of The Baseline||Characteristics Of Patients Treated With Eculizumab In The  Australian Cohort",Meeting Room 217,Danny Hsu,HSANZ Free Communications 7: Non-Malignant,Liverpool Hospital,16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/083_Khalafallah.pdf,Abstract 83,Treatment of iron deficiency anaemia of late pregnancy with a single intravenous||ferric carboxymaltose or iron polymaltose infusion versus daily oral iron||sulphate (TIDAL): a prospective randomised controlled trial||,Meeting Room 217,Alhossain Khalafallah,HSANZ Free Communications 7: Non-Malignant,Launceston General Hospital,16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/084_Kivivali.pdf,Abstract 84,Emerging Insights into Efficacy of Aplastic Anaemia Management Practices from||the Australian Aplastic Anaemia Registry,Meeting Room 217,Leah Kivivali,HSANZ Free Communications 7: Non-Malignant,Monash University,16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/085_Chiu.pdf,Abstract 85,Scl and Lyl1 are critical for proplatelet formation and platelet function,Meeting Room 217,Sung Kai Chiu,HSANZ Free Communications 7: Non-Malignant,Australian Centre for Blood Diseases/The Alfred Hospital,16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/086_Jones.pdf,Abstract 86,Novel next generation sequencing based minimal residual disease testing||utilising non-conventional molecular targets in acute myeloid leukaemia,Meeting Room 220,Kate Jones,HSANZ Free Communications 8: Acute Myeloid Leukaemia & Myelodysplasia,Peter MacCallum Cancer Centre,16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/087_Sillar.pdf,Abstract 87,Reactive oxygen species promote leukaemogenesis via altered redox signalling||pathways in FLT3-ITD+ acute myeloid leukaemia,Meeting Room 220,Jonathan Sillar,HSANZ Free Communications 8: Acute Myeloid Leukaemia & Myelodysplasia,"University of Newcastle, Calvary Mater Newcastle",16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/088_Vu.pdf,Abstract 88,miR-10a as a Predictive Biomarker in Normal Karyotype (NK) Acute Myeloid||Leukaemia (AML).,Meeting Room 220,Thi Thanh Vu,HSANZ Free Communications 8: Acute Myeloid Leukaemia & Myelodysplasia,St Vincent's Center for Applied Medical Research,16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/089_Jeffrey.pdf,Abstract 89,Low-Dose Cytarabine and Thioguanine Based Metronomic Chemotherapy (STIMULus) as||Salvage in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukaemia||(AML),Meeting Room 220,Anthony Jeffrey,HSANZ Free Communications 8: Acute Myeloid Leukaemia & Myelodysplasia,The University of Sydney,16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/090_Schwarer.pdf,Abstract 90,A Single High-Dose Cytarabine (HiDAC) During Induction-Consolidation May Not be||Adequate for Patients with a New Diagnosis of Acute Myeloid Leukaemia (AML) not||Planned for Allogeneic Haematopoietic Stem Cell Transplantation (alloHSCT) in||1st Complete Remission (CR1),Meeting Room 220,Anthony Schwarer,HSANZ Free Communications 8: Acute Myeloid Leukaemia & Myelodysplasia,Box Hill Hospital,16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/091_Watts.pdf,Abstract 91,Determining mechanisms of resistance to Azacitidine (Aza) in Myelodysplastic||(MDS) syndromes and Acute Myeloid Leukaemia (AML) using an in-vitro model,Meeting Room 220,Sophie Watts,HSANZ Free Communications 8: Acute Myeloid Leukaemia & Myelodysplasia,South Australian Health and Medical Research Institute,16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/092_Spitalnik.pdf,Abstract 92,"Stored RBC transfusions: Iron, inflammation, immunity, infection",Meeting Room 212 & 213,Steven Spitalnik,ANZSBT & HSANZ: RBC,Columbia University Medical Center,16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/093_Perkins.pdf,Abstract 93,Kruppeling Erythropoiesis,Meeting Room 212 & 213,Andrew Perkins,ANZSBT & HSANZ: RBC,Mater Research Institute,16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/094_Dzik.pdf,Abstract 94,The air they breathe||,Meeting Room 212 & 213,Walter H. Dzik,ANZSBT & HSANZ: RBC,Massachusetts General Hospital,16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/095_Esmon.pdf,Abstract 95,"Involvement of the protein C pathway in cancer, kidney disease and malaria",Meeting Room 219,Charles Esmon,ASTH Symposium: Inflammation thrombosis,Oklahoma Medical Research Foundation,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/096_Cowan.pdf,Abstract 96,Cross-species incompatibility of thrombomodulin: Implications and solutions for||xenotransplantation,Meeting Room 219,Peter Cowan,ASTH Symposium: Inflammation thrombosis,St Vincent's Hospital,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/097_Weitz.pdf,Abstract 97,Valves thrombosis||,Meeting Room 219,Jeffrey Weitz,ASTH Symposium: Contact pathways,McMaster University,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/098_McFadyen.pdf,Abstract 98,Being in the right place at the right time: Targeted anti-thrombotic approaches,Meeting Room 219,James McFadyen,ASTH Symposium: Contact pathways,Alfred Hospital,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/099_Roxby.pdf,Abstract 99,Thromboelastography,Meeting Room 219,David Roxby,ASTH Symposium: Diagnostic tools,Flinders University,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/100_Nesbitt.pdf,Abstract 100,A shear based microfluidic device to monitor platelet function: Application to||von Willebrand disease screening,Meeting Room 219,Warwick Nesbitt,ASTH Symposium: Diagnostic tools,RMIT University,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/101_Andrews.pdf,Abstract 101,Soluble platelet proteins that help evaluate thrombocytopenia and stratify||bleeding risk,Meeting Room 219,Robert Andrews,ASTH Symposium: Diagnostic tools,Monash University,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/102_Morel-Kopp.pdf,Abstract 102,Identification of a new dysfunctional platelet P2Y12 receptor variant in a||family with bleeding history,Meeting Room 219,Marie-Christine Morel-Kopp,ASTH Free Communications 1,Royal North Shore Hospital,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/103_Duncan.pdf,Abstract 103,Establishment of a Diagnostic Algorithm for Heparin Induced Thrombocytopenia||that Includes a Rapid Chemiluminescent Immunoassay as the Initial Laboratory||Test.,Meeting Room 219,Elizabeth Duncan,ASTH Free Communications 1,SA Pathology,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/104_Tiao.pdf,Abstract 104,Improving Microangiopathic Thrombocytopenia(MAT) diagnosis in the Asia-Pacific||region by standardisation of the ADAMTS-13 assay,Meeting Room 219,Jim Tiao,ASTH Free Communications 1,WACTH Murdoch University,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/105_Chun.pdf,Abstract 105,MYH9 disorders are not uncommon in Australia and New Zealand: results from a||platelet next generation sequencing (NGS) project,Meeting Room 219,Yenna Chun,ASTH Free Communications 1,Kolling Institute of Medical Research,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/106_Simonova.pdf,Abstract 106,Point-of-care Testing of Coagulation during Extracorporeal Membrane Oxygenation||in a Sheep Model,Meeting Room 219,Gabriela Simonova,ASTH Free Communications 1,Australian Red Cross Blood Service,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/107_Ginsborg.pdf,Abstract 107,Diagnostic algorithm in Heparin Induced Thrombotic Thrombocytopenia (HITT):||review of serotonin release assay results,Meeting Room 219,Lette Ginsborg,ASTH Free Communications 1,"St Vincent's Hospital, Sydney",14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/108_Dunkley.pdf,Abstract 108,Rare hereditary bleeding disorders,Meeting Room 219,Scott Dunkley,ASTH: Bleeding disorders,Royal Prince Alfred Hospital,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/109_Rabbolini.pdf,Abstract 109,Genetic testing in the investigation of patients with suspected inherited||thrombocytopenia,Meeting Room 219,David Rabbolini,ASTH: Bleeding disorders,Royal North Shore Hospital,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/110_Tran.pdf,Abstract 110,Acquired haemophilia,Meeting Room 219,Huyen Tran,ASTH: Bleeding disorders,The Alfred Hospital,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/111_Medcalf.pdf,Abstract 111,Brain trauma and the role of anti-fibrinolytic agents,Meeting Room 219,Robert Medcalf,ASTH Symposium: Antifibrinolysis (TA) in clinical,Monash University,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/112_Myles.pdf,Abstract 112,Tranexamic acid in cardiac surgery,Meeting Room 219,Paul Myles,ASTH Symposium: Antifibrinolysis (TA) in clinical,Alfred Hospital,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/113_Campbell.pdf,Abstract 113,Thrombolysis vs thrombectomy in stroke,Meeting Room 219,Bruce Campbell,ASTH Symposium: Antifibrinolysis (TA) in clinical,Royal Melbourne Hospital,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/114_Brighton.pdf,Abstract 114,Residual Vein Thrombus Does Not Predict For Recurrent Vein Thrombosis in the||ASPIRE study,Meeting Room 219,Timothy Brighton,ASTH Free Communications 2,SEALS,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/115_Yuen.pdf,Abstract 115,Venous Thromboembolism (VTE) in Patients with Primary Central Nervous System||Lymphoma (PCNSL) Receiving R-MPV,Meeting Room 219,Hiu Lam Agnes Yuen,ASTH Free Communications 2,Monash Health,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/116_Barnes.pdf,Abstract 116,Phase 3 Trial Results Demonstrating Efficacy and Safety of rIX-FP in Children||with Haemophilia B,Meeting Room 219,Christopher Barnes,ASTH Free Communications 2,Royal Children's Hospital,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/117_McRae.pdf,Abstract 117,Current practice regarding prophylaxis in patients with moderate and severe||haemophilia A in Australia,Meeting Room 219,Simon McRae,ASTH Free Communications 2,Royal Adelaide Hospital,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/118_McCaughan.pdf,Abstract 118,Choice of anticoagulation in veno-thromboembolic disease in obese patients,Meeting Room 219,Georgia McCaughan,ASTH Free Communications 2,Westmead Hospital,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/119_Baker.pdf,Abstract 119,Clinical utility of specific DOAC plasma concentration assessments in the ASTH||Anticoagulation Reversal and Events Study Collaborative (ARES1),Meeting Room 219,Ross Baker,ASTH Free Communications 2,"Perth Blood Institute, WACTH Murdoch University",15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/120_Williams.pdf,Abstract 120,Pulmonary hypertension: What Haematologists need to know,Meeting Room 219,Trevor Williams,ASTH Symposium: Pulmonary HPT & vascular intervention,The Alfred Hospital,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/121_McGiffin.pdf,Abstract 121,Pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension,Meeting Room 219,David McGiffin,ASTH Symposium: Pulmonary HPT & vascular intervention,Alfred Hospital,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/122_Vrazas.pdf,Abstract 122,Localised intervention,Meeting Room 219,John Vrazas,ASTH Symposium: Pulmonary HPT & vascular intervention,Melbourne Institute of Vascular and Interventional Radiology,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/123_Chan Wan Kai.pdf,Abstract 123,ISTH reversal guidelines,Meeting Room 219,Noel Chan Wan Kai,ASTH Symposium: NOAC reversal,Monash University,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/124_Weitz.pdf,Abstract 124,Strategies to Minimize the Risk of Bleeding with Direct Oral Anticoagulants,Meeting Room 219,Jeffrey Weitz,ASTH Symposium: NOAC reversal,McMaster University,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/125_Baker.pdf,Abstract 125,ARES update,Meeting Room 219,Ross Baker,ASTH Symposium: NOAC reversal,"Perth Blood Institute, WACTH Murdoch University",15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/126_Hoffmeister.pdf,Abstract 126,AMR (1) – Platelet production,Meeting Room 212 & 213,Karin Hoffmeister,ANZSBT & ASTH Symposium: Platelets,Brigham and Women's Hospital,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/127_Chen.pdf,Abstract 127,Procoagulant platelets contribute to occlusive thrombus formation and are formed||via the Cyclophilin D dependent necrosis pathway,Meeting Room 212 & 213,Vivien Chen,ANZSBT & ASTH Symposium: Platelets,Concord General Hospital and ANZAC Research Institute,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/128_Josefsson.pdf,Abstract 128,"Apoptotic death prevents the functional decline of platelets in vivo, but||apoptosis is not required for the development of the platelet storage lesion",Meeting Room 212 & 213,Emma Josefsson,ANZSBT & ASTH Symposium: Platelets,Walter & Eliza Hall Institute of Medical Research,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/129_McRae.pdf,Abstract 129,Development of Australian guidelines for the treatment of haemophilia,Meeting Room 219,Simon McRae,ASTH Free Communications 3,Royal Adelaide Hospital,16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/130_Stevens.pdf,Abstract 130,Anticoagulation for Venous Thromboembolism (VTE) and Rates of Per Vaginal||Bleeding in Pre-Menopausal Women,Meeting Room 219,Hannah Stevens,ASTH Free Communications 3,Northern Hospital/Australian Clinical Labs,16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/131_Slocombe.pdf,Abstract 131,Venous thromboembolism rates and validation of the Khorana score in diffuse||large B-cell lymphoma,Meeting Room 219,Alison Slocombe,ASTH Free Communications 3,"Monash Haematology, Monash Health",16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/132_Burchall.pdf,Abstract 132,"Aberrant Haemostasis from OCP, but not Metformin use in Polycystic Ovarian||Syndrome (PCOS)",Meeting Room 219,Genia Burchall,ASTH Free Communications 3,RMIT University,16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/133_Tran.pdf,Abstract 133,The risk of inhibitor development among congenital haemophilia patients who||receive factor concentrate replacement via continuous infusion,Meeting Room 219,Huyen Tran,ASTH Free Communications 3,The Alfred Hospital,16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/134_Joseph.pdf,Abstract 134,Preoperative assessment of bleeding risk – how are we really performing?,Meeting Room 219,Joanne Joseph,ASTH Free Communications 3,St Vincent's Hospital Sydney,16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/135_McLintock.pdf,Abstract 135,Obstetric DIC,Meeting Room 219,Claire McLintock,ASTH Symposium: DIC,National Women's Health,16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/136_Esmon.pdf,Abstract 136,"The protein C pathway and histone participation in DIC, thrombosis, organ||failure and death",Meeting Room 219,Charles Esmon,ASTH Symposium: DIC,Oklahoma Medical Research Foundation,16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/137_Brighton.pdf,Abstract 137,DIC in cancer,Meeting Room 219,Timothy Brighton,ASTH Symposium: DIC,SEALS,16/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/138_McMillan.pdf,Abstract 138,Disaster preparedness and recovery,Meeting Room 212 & 213,Alison McMillan,ANZSBT: Disaster preparedness and recovery,Department of Health & Human Servic,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/139_Waters.pdf,Abstract 139,Disasters I have contributed to,Meeting Room 212 & 213,Neil Waters,ANZSBT: Disaster preparedness and recovery,Monash University,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/140_Flanagan.pdf,Abstract 140,Reflections on the Christchurch earthquake,Meeting Room 212 & 213,Peter Flanagan,ANZSBT: Disaster preparedness and recovery,New Zealand Blood Service,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/141_Spitalnik.pdf,Abstract 141,Pathophysiology of Hemolytic Transfusion Reactions||,Meeting Room 212 & 213,Steven Spitalnik,ANZSBT: Transfusion reactions,Columbia University Medical Center,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/142_Luban.pdf,Abstract 142,Paediatric transfusion reactions and alloimmunisation||,Meeting Room 212 & 213,Naomi Luban,ANZSBT: Transfusion reactions,Children's National Medical Center,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/143_Thornton.pdf,Abstract 143,Investigation of complex Rh antibody problems in pregnancy,Meeting Room 212 & 213,Nicole Thornton,ANZSBT: Pregnancy,NHS Blood and Transplant,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/144_Kidson-Gerber.pdf,Abstract 144,Haemoglobinopathy and thalassaemia management in pregnnacy (TBC),Meeting Room 212 & 213,Giselle Kidson-Gerber,ANZSBT: Pregnancy,Prince of Wales Hospital,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/145_Pennell.pdf,Abstract 145,Single dose Anti-D prophylaxis in pregnancy: is it time to change?,Meeting Room 212 & 213,Craig Pennell,ANZSBT: Pregnancy,The University of Western Australia,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/146_Dzik.pdf,Abstract 146,100 milion RBC transfusions each year…but do they deliver oxygen?,Meeting Room 212 & 213,Walter H. Dzik,ANZSBT: Paediatric  and neonatal transfusion,Massachusetts General Hospital,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/147_Luban.pdf,Abstract 147,Paediatric PBM||,Meeting Room 212 & 213,Naomi Luban,ANZSBT: Paediatric  and neonatal transfusion,Children's National Medical Center,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/148_Liley.pdf,Abstract 148,Module 6: Neonatal and Paediatric Patient Blood Management,Meeting Room 212 & 213,Helen Liley,ANZSBT: Paediatric  patient blood management,Mater Misericordiae Ltd,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/149_Crighton.pdf,Abstract 149,International neonatal and paediatric Patient Blood Management guidelines,Meeting Room 212 & 213,Gemma Crighton,ANZSBT: Paediatric  patient blood management,Royal Children's Hospital,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/150_Thornton.pdf,Abstract 150,The immunohaematology toolbox for solving complex antibody cases,Meeting Room 212 & 213,Nicole Thornton,ANZSBT/ ISBT Academy Session: Resolving tricky issues in the transfusion laboratory,NHS Blood and Transplant,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/151_Rushford.pdf,Abstract 151,Dealing with challenging antibodies,Meeting Room 212 & 213,Kylie Rushford,ANZSBT/ ISBT Academy Session: Resolving tricky issues in the transfusion laboratory,Monash Health,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/152_Oh.pdf,Abstract 152,Antibody soup: Challenging transfusion management issues in thalassaemia major,Meeting Room 212 & 213,Danielle Oh,ANZSBT/ ISBT Academy Session: Resolving tricky issues in the transfusion laboratory,Monash Health,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/153_Dzik.pdf,Abstract 153,How to get your work published in a medical journal,Meeting Room 211,Walter H. Dzik,ANZSBT Masterclass: How to get published in a peer reviewed journal (Sunny Dzik),Massachusetts General Hospital,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/154_Ruseckaite.pdf,Abstract 154,Risk factors for 30-day mortality in critically bleeding patients requiring||massive transfusion within 24 hours of admission to the Intensive Care Unit,Meeting Room 212 & 213,Rasa Ruseckaite,ANZSBT - Free Communications - Clinical,"Department of Epidemiology and Preventive Medicine, School of Public Health and",15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/155_Swain.pdf,Abstract 155,"Transfusion-Related Acute Lung Injury (TRALI): A Review of Reported TRALI Cases||in Queensland, Australia, between 1999 and June 2016",Meeting Room 212 & 213,Fiona Swain,ANZSBT - Free Communications - Clinical,Australian Red Cross Blood Service,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/156_Higgins.pdf,Abstract 156,"Determining the frequency, costs and outcomes of red blood cell transfusion in||hospitalised patients: a pilot study",Meeting Room 212 & 213,Alisa Higgins,ANZSBT - Free Communications - Clinical,Monash University,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/157_Behan.pdf,Abstract 157,Gastrointestinal bleeding-red blood cell transfusion and patient blood||management practice in a metropolitan hospital,Meeting Room 212 & 213,Daniel Behan,ANZSBT - Free Communications - Clinical,St Vincents Hospital Sydney,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/158_Crighton.pdf,Abstract 158,"The Australian haemoglobinopathy registry: aims, plans and pilot data",Meeting Room 212 & 213,Gemma Crighton,ANZSBT - Free Communications - Clinical,Royal Children's Hospital,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/159_Fung.pdf,Abstract 159,Preliminary data on cost of IVIg & SCIg treatment in adult Australian patients,Meeting Room 212 & 213,Lin Fung,ANZSBT - Free Communications - Clinical,University of the Sunshine Coast,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/160_Hyland.pdf,Abstract 160,"Can extended genotyping, using a comprehensive and targeted blood group||sequencing, assist in resolving complex serology problems in chronic transfused||patients?",Meeting Room 217,Catherine Hyland,ANZSBT Free Communications - Laboratory,Australian Red Cross Blood Service,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/161_Lopez.pdf,Abstract 161,A novel molecular mechanism in RHD caused the deletion of Exon 9 resulting in a||partial DEL phenotype,Meeting Room 217,Genghis Lopez,ANZSBT Free Communications - Laboratory,Australian Red Cross Blood Service,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/162_Wilkes.pdf,Abstract 162,Managing anti-CD38 (Daratumumab) interference with pre-transfusion testing in a||busy hospital transfusion laboratory,Meeting Room 217,Anne-Marie Wilkes,ANZSBT Free Communications - Laboratory,St Vincent's Pathology,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/163_Badami.pdf,Abstract 163,Platelets in Platelet Additive Solution (PAS) cause fewer allergic reactions||compared to platelets in plasma – data from NZBS Haemovigilance and possible||mechanisms,Meeting Room 217,Krishna Badami,ANZSBT Free Communications - Laboratory,New Zealand Blood Service,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/164_Oh.pdf,Abstract 164,The challenges of providing phenotyped matched red cells in contemporary||Australian practice,Meeting Room 217,Danielle Oh,ANZSBT Free Communications - Laboratory,Monash Health,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/165_Marks.pdf,Abstract 165,Extending the post-thaw shelf-life of cryoprecipitate,Meeting Room 217,Denese Marks,ANZSBT Free Communications - Laboratory,Australian Red Cross Blood Service,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/166_Flanagan.pdf,Abstract 166,An update on emerging infections threats to the safety of the blood supply,Meeting Room 212 & 213,Peter Flanagan,ANZSBT - An update on emerging infectious threats,New Zealand Blood Service,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/167_Buttery.pdf,Abstract 167,What is the role for immunoglobulin products in the era of better vaccinations||and new drugs?,Meeting Room 212 & 213,Jim Buttery,ANZSBT - An update on emerging infectious threats,Monash University,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/168_Thornton.pdf,Abstract 168,Immunohaematology case studies - Interactive!,Meeting Room 219,Nicole Thornton,"ANZSBT Masterclass: Transfusion case studies, troubleshooting in immunohaematology lab (Nicole Thornton )",NHS Blood and Transplant,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/169_Luban.pdf,Abstract 169,Paediatric transfusion cases or clinical problems,Meeting Room 214,Naomi Luban,ANZSBT Masterclass: Paediatric transfusion cases or clinical problems (Naomi Luban),Children's National Medical Center,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/170_Cohen.pdf,Abstract 170,Comprehensive patient assessment: Rhetoric or reality?,Meeting Room 220,Emma Cohen,Nurses Symposium: Symptom management,Austin Health,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/171_Cormie.pdf,Abstract 171,Exercise medicine,Meeting Room 220,Prue Cormie,Nurses Symposium: Symptom management,Australian Catholic University,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/172_Klarica.pdf,Abstract 172,Positive Change for Life,Meeting Room 220,Daniela Klarica,Nurses Symposium: Symptom management,Alfred Health,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/173_Gates.pdf,Abstract 173,Unmet needs of patients attending a Haematology Nurse-led Survivorship clinic||,Meeting Room 220,Priscilla Gates,Nurses Symposium: Free Communication,Austin Health,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/174_Panek-Hudson.pdf,Abstract 174,Listening to our colleagues – Essential Primary care feedback on LTFU care plans,Meeting Room 220,Yvonne Panek-Hudson,Nurses Symposium: Free Communication,"Royal Melbourne Hospital & Peter MacCallum Cancer Centre, Victorian Comprehensiv",13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/175_Joyce.pdf,Abstract 175,A novel approach in delivering vaccinations following an autologous stem cell||transplant,Meeting Room 220,Trish Joyce,Nurses Symposium: Free Communication,Peter MacCallum Cancer Centre,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/176_Kurtin.pdf,Abstract 176,Caregiver self-efficacy||,Meeting Room 220,Sandra Kurtin,Nurses Symposium: Carer preparedness,The University of Arizona Cancer Center,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/177_Presta.pdf,Abstract 177,Development and implementation of a multidisciplinary (MD) support program for||carers of patients undergoing allogeneic haematopoietic stem cell||transplantation,Meeting Room 220,Maria Presta,Nurses Symposium: Carer preparedness,Royal Melbourne Hospital,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/178_Iaconis.pdf,Abstract 178,Living the experience as a carer,Meeting Room 220,Marcella Iaconis,Nurses Symposium: Carer preparedness,,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/179_Trubiano.pdf,Abstract 179,Addressing antibiotic allergy in haematology patients - pathways to better||prescribing,Meeting Room 220,Jason Trubiano,Nurses Symposium: Bugs and drugs,Austin Health,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/180_Rowan.pdf,Abstract 180,Drug interactions with anti-infective agents in haematological malignancies,Meeting Room 220,Gail Rowan,Nurses Symposium: Bugs and drugs,Peter MacCallum Cancer Centre,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/181_Roberts.pdf,Abstract 181,Setting the scene - clinical scenario,Meeting Room 220,Andrew Roberts,Nurses Symposium: Case study discussion - Allografting a Jehovah's Witness patient with MDS,Walter and Eliza Hall Institute of Medical Research,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/182_Mineely.pdf,Abstract 182,Nursing considerations,Meeting Room 220,Siobhan Mineely,Nurses Symposium: Case study discussion - Allografting a Jehovah's Witness patient with MDS,Monash Health,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/183_Presta.pdf,Abstract 183,Ethical implications of allografting a Jehovah Witness patient with MDS,Meeting Room 220,Maria Presta,Nurses Symposium: Case study discussion - Allografting a Jehovah's Witness patient with MDS,Royal Melbourne Hospital,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/184_McCarthy.pdf,Abstract 184,Fulfilling the vision of youth-friendly cancer care: How well are we doing?,Meeting Room 220,Maria McCarthy,Nurses Symposium: Focus on AYA,The Royal Children's Hospital,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/185_Haywood.pdf,Abstract 185,A practical review of the haematology nurse's role in the care of adolescent and||young adults,Meeting Room 220,Peter Haywood,Nurses Symposium: Focus on AYA,Royal Melbourne Hospital,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/186_Kurtin.pdf,Abstract 186,Safe delivery and management of new agents in multiple myeloma,Meeting Room 220,Sandra Kurtin,Nurses Masterclass: Safe delivery and management of new agents in multiple myeloma (Sandra Kurtin),The University of Arizona Cancer Center,14/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/187_Button.pdf,Abstract 187,Hope For The Best Yet Prepare For The Rest: A Systematic Review of Advance Care||Planning Prior To Stem Cell Transplantation||,Meeting Room 220,Elise Button,Nurses Symposium: Free Communication,Queensland University of Technology,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/188_Abo.pdf,Abstract 188,Hospital and Home Based Exercise Program Following Allogeneic Haematopoietic||Stem Cell Transplantation,Meeting Room 220,Shaza Abo,Nurses Symposium: Free Communication,Melbourne Health,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/189_Meijer (nee Kenny).pdf,Abstract 189,Miss A’s Treatment Journey Through a Double Cord Stem Cell Transplant ; The||Importance of Palliative Care Input in Stem Cell Transplant Patients Care; A||Case Study Presentation,Meeting Room 220,Natalie Meijer (nee Kenny),Nurses Symposium: Free Communication,Canterbury District Health Board,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/190_Levak.pdf,Abstract 190,Changing indications for autologous HSCT at St Vincent's Hospital and the impact||of severe auto-immune conditions such as Multiple Sclerosis and Scleroderma at||the general ward level.,Meeting Room 220,Serafina Levak,Nurses Symposium: Free Communication,St Vincents Public Hospital,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/191_Horne.pdf,Abstract 191,Autologous stem cell transplant In patients with cardiac AL amyloidosis post an||orthotopic heart transplant: a case study,Meeting Room 220,Annabel Horne,Nurses Symposium: Free Communication,St Vincent's Hospital,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/192_Downs.pdf,Abstract 192,A Collaborative Approach in the Management of Late Onset Grade IV skin GVHD of||an Adolescent Male Post Allogenic Bone Marrow Transplant,Meeting Room 220,Erin Downs,Nurses Symposium: Free Communication,Royal Brisbane & Women's Hospital,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/193_King.pdf,Abstract 193,"myeNURSE: working together to improve outcomes for those with myeloma, a focus||on best practice and information sharing",Meeting Room 220,Tracy King,Nurses Symposium: Free Communication,Royal Prince Alfred Hospital,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/194_Steele.pdf,Abstract 194,Trial Of The Use Of Methoxyflurane Inhalation For Analgesic Control During Bone||Marrow Biopsy In A Haematology Outpatient Department.,Meeting Room 220,Andrew Steele,Nurses Symposium: Free Communication,Sir Charles Gairdner Hospital,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/195_Krishna.pdf,Abstract 195,Facilitating Effective Transition from Secondary to Primary Care: Trial of a New||Nurse-Led Model for Haematology Patients Post Cancer Treatment Discharge,Meeting Room 220,Anne Krishna,Nurses Symposium: Free Communication,Palmerston North Hospital,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/196_Vassili.pdf,Abstract 196,Understanding MPNs,Meeting Room 220,Catherine Vassili,Nurses How To - Understanding MPNs,MDS/MPN Special Practice Network,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/197_Wall.pdf,Abstract 197,Understanding cytogenetics,Meeting Room 217,Meaghan Wall,Nurses How To - session 2,St Vincent's Hospital,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/198_Botti.pdf,Abstract 198,Developing a robust clinical audit: How to get from your idea to||presentation/publication,Meeting Room 218,Mari Botti,Nurses How To - session 3,Deakin University,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/199_Hart.pdf,Abstract 199,Allograft donor selection,Meeting Room 220,Cathie Hart,Nurses Symposium: Focus on Transplant/Apheresis,Australian Red Cross Blood Service,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/200_Hill.pdf,Abstract 200,Apheresis case study: What to do when you’re not U,Meeting Room 220,Aaron Hill,Nurses Symposium: Focus on Transplant/Apheresis,Victorian Comprehensive Cancer Centre,15/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/201_Elwood.pdf,Abstract 201,Establishment of an Australian cord blood-derived iPSC bank for clinical use,Meeting Room 211,Ngaire Elwood,BMTSAA Symposium: Novel cellular therapies,Murdoch Childrens Research Institute,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/202_Crompton.pdf,Abstract 202,How could cord blood help children with cerebral palsy?,Meeting Room 211,Kylie Crompton,BMTSAA Symposium: Novel cellular therapies,Murdoch Childrens Research Institute,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/203_Pepe.pdf,Abstract 203,Cord blood adjunct therapy in cardiopulmonary-bypass surgery for congenital||heart diseases,Meeting Room 211,Salvatore Pepe,BMTSAA Symposium: Novel cellular therapies,Murdoch Childrens Research Institute,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/204_Fleming.pdf,Abstract 204,Immunotherapy in acute lymphoblastic leukaemia,Meeting Room 211,Shaun Fleming,BMTSAA Symposium: Immunotherapies,Alfred Health,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/205_Watson.pdf,Abstract 205,Initial comparison of 3 apheresis platforms for supporting the collection of||CD3+ cells for CAR-T production,Meeting Room 211,Doug Watson,BMTSAA Symposium: Immunotherapies,Cell Therapies Pty Ltd,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/206_Tong.pdf,Abstract 206,Pre-apheresis T cell counts can be used to calculate additional blood volume to||be processed for donor lymphocyte cryopreservation,Meeting Room 211,Daochen Tong,BMTSAA Symposium: Free Communications: 'Cases from the bench',Westmead and Children's Hospital,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/207_Palladinetti.pdf,Abstract 207,Inter-laboratory Comparison of Viable CD34+ in Aliquots of Cryopreserved HPC,Meeting Room 211,Patricia Palladinetti,BMTSAA Symposium: Free Communications: 'Cases from the bench',Agency for Clinical Innovation - BMT Network,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/208_Chiappini.pdf,Abstract 208,"Sepax II vs Spectra Optia, a comparison of two technologies for red blood cell||depletion",Meeting Room 211,Paul Chiappini,BMTSAA Symposium: Free Communications: 'Cases from the bench',Pathwest Fiona Stanley Hospital,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/209_Trickett.pdf,Abstract 209,"Thaw, Wash and Infusion of Unrelated Donor HPC, Cord Blood",Meeting Room 211,Annette Trickett,BMTSAA Symposium: Free Communications: 'Cases from the bench',SEALS Pathology,13/11/2016
http://dzdecqfjn907w.cloudfront.net/J000523/Abstracts/210_Hill.pdf,Abstract 210,BMTL Pathwest: from concept to production,Meeting Room 211,Celeste Hill,BMTSAA Symposium: Free Communications: 'Cases from the bench',Pathwest BMTL Fiona Stanley Hospital,13/11/2016